According to the packet definition, trisomy 13 is caused by the presence of an extra chromosome 13. The packet lists complete and mosaic trisomy 13 as subtypes without further description. No genes or inheritance patterns are certified, so inheritance is not described here.

The packet certifies no diagnostic methods or criteria for trisomy 13, and diagnostic information is therefore not described here.

The packet certifies no foundational therapies and no FDA-approved treatments for trisomy 13. Treatment information is not certified in this packet.

The packet does not include natural history information for trisomy 13, so prognosis is not described here.

The packet lists three ClinicalTrials.gov records associated with trisomy 13. NCT07643896, sponsored by BillionToOne Inc., is titled as the ADVANCE study of a circulating fetal cell-based approach to non-invasive fetal risk assessment; it is listed as recruiting. NCT07165743, from Haseki Training and Research Hospital, is titled as an evaluation of fetal bladder emptying as a negative predictive marker for chromosomal abnormalities; it is listed as active, not recruiting. NCT06740162, the Physical Activity and Community EmPOWERment Project from the University of North Carolina, Chapel Hill, is listed as recruiting. Trial titles do not establish that any intervention is effective. The packet names two patient organizations: soft.org.uk and trisomy.org.